<DOC>
	<DOCNO>NCT00742859</DOCNO>
	<brief_summary>Prevention stroke patient atrial fibrillation ( AF ) . Hypothesis : In patient non-valvular AF , orally administer betrixaban provide similar good efficacy safety warfarin offer advantage require dose adjustment due INRs outside target range 2.0 3.0 consistent level anticoagulation time .</brief_summary>
	<brief_title>Phase 2 Study Safety , Tolerability Pilot Efficacy Oral Factor Xa Inhibitor Betrixaban Compared Warfarin</brief_title>
	<detailed_description>To assess safety tolerability betrixaban dose 40 mg , 60 mg 80 mg give orally day least 3 month compare dose-adjusted warfarin patient non-valvular atrial fibrillation ( AF ) . This Phase 2 , exploratory , randomize , parallel group , multicenter , active comparator , dose find study patient document non-valvular AF . Patients randomize ( 1:1:1:1 ) 1 4 treatment group ( approximately 125 patient per group ) use IVRS . A dynamic randomization use balance patient country , concurrent aspirin use ( yes ) antecedent warfarin ( yes ) . The study open label randomization warfarin versus betrixaban , three daily dos betrixaban , 40 mg , 60 mg 80 mg , double-blind ( identical capsule three dose level ) . The warfarin-treated patient manage accord center 's usual clinical routine INR monitoring dose-adjustments order maintain target INR 2.0 3.0 maximum interval four week . No loading dose dose titration use betrixaban . The betrixaban dose ingest evening ( e.g . bedtime ) , preferably least 2 hour even meal . Note : acenocumerol may substitute warfarin indicated local practice .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Acenocoumarol</mesh_term>
	<mesh_term>Factor Xa Inhibitors</mesh_term>
	<criteria>Male female , age ≥18 year . If patient woman , must without reproductive potential ( i.e. , postmenopausal ≥2 year hysterectomy ) . AF time enrollment ( randomization ) document within last year Holter , ECG , rhythm strip , pacemaker intracardiac recording , result indication anticoagulation warfarin , acenocumerol , phenprocoumon , Vitamin K antagonist opinion treat physician . One follow risk factor ( ) stroke : 1 . Age 75 year old . 2 . Prior stroke , TIA systemic ( i.e. , central nervous system ) embolus least 30 day remote time screen . 3 . Symptomatic congestive heart failure within 3 month echocardiography , radionuclide study contrast angiography . 4 . Hypertension require pharmacological treatment . 5 . Diabetes . 6 . Age 55 year older previous coronary artery disease know peripheral artery disease . Body weight less 40 kg ( 88 lb ) . Need either hemodialysis peritoneal dialysis ( likely require within one year ) . AF due reversible cause ( e.g. , thyrotoxicosis , pericarditis , cardiac surgery , pulmonary embolism ) . Mechanical prosthetic valve ( bioprosthetic valve allow ) valvular disease likely operate within one year . History ( include family history ) symptoms congenital acquire bleed disorder vascular malformation ; history intracranial , retroperitoneal , intraocular bleeding within last 6 month ; felt high risk bleed reason include significant liver disease . This also include gastrointestinal bleeding within 90 day randomization endoscopically verified ulcer disease within 30 day screen . Conditions AF require chronic anticoagulation ( e.g . prosthetic mechanical heart valve ) . Persistent , uncontrolled hypertension ( SBP &gt; 160 mm Hg repeat measurement ) . Active infective endocarditis . Scheduled major surgery . Planned pulmonary vein ablation surgical procedure cure AF flutter . Recent ischemic stroke , systemic embolic event acute coronary syndrome within 30 day . Severe comorbid condition life expectancy ≤1 year . Previous known history genetic coagulopathy ( e.g. , Factor V Leiden , Protein C Deficiency , Protein S Deficiency , Antiphospholipid Syndrome , etc. ) . Evidence Screening : 1 . Platelet count &lt; 100,000/mm3 . 2 . Serum alanine aminotransferase ( ALT ) aspirate aminotransferase ( AST ) &gt; 2 time ULN . 3 . A history ( include family history ) `` Long QT Syndrome '' . Aspirin &gt; 162 mg daily . Use verapamil ( pending availability drug interaction study betrixaban ) . Active alcohol drug abuse , psychosocial reason make study participation impractical . Use investigational drug device within past 30 day . Inability comply INR monitoring protocolrelated activity . Unable give write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Atrial Fibrillation</keyword>
	<keyword>Betrixaban</keyword>
	<keyword>Factor Xa inhibitor</keyword>
	<keyword>Warfarin</keyword>
</DOC>